• Lei L Chen, Jonathan C Trent, Elsie F Wu, Gregory N Fuller, Latha Ramdas, Wei Zhang, Austin K Raymond, Victor G Prieto, Caroline O Oyedeji, Kelly K Hunt, Raphael E Pollock, Barry W Feig, Kimberly J Hayes, Haesun Choi, Homer A Macapinlac, Walter Hittelman, Marco A Velasco, Shreyaskumar Patel, Michael A Burgess, Robert S Benjamin, and Marsha L Frazier.
• Department of Sarcoma, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA. llchen@ mdanderson.org
• Cancer Res. 2004 Sep 1; 64 (17): 5913-9.

AbstractKIT gain of function mutations play an important role in the pathogenesis of gastrointestinal stromal tumors (GISTs). Imatinib is a selective tyrosine kinase inhibitor of ABL, platelet-derived growth factor receptor (PDGFR), and KIT and represents a new paradigm of targeted therapy against GISTs. Here we report for the first time that, after imatinib treatment, an additional specific and novel KIT mutation occurs in GISTs as they develop resistance to the drug. We studied 12 GIST patients with initial near-complete response to imatinib. Seven harbored mutations in KIT exon 11, and 5 harbored mutations in exon 9. Within 31 months, six imatinib-resistant rapidly progressive peritoneal implants (metastatic foci) developed in five patients. Quiescent residual GISTs persisted in seven patients. All six rapidly progressive imatinib-resistant implants from five patients show an identical novel KIT missense mutation, 1982T-->C, that resulted in Val654Ala in KIT tyrosine kinase domain 1. This novel mutation has never been reported before, is not present in pre-imatinib or post-imatinib residual quiescent GISTs, and is strongly correlated with imatinib resistance. Allelic-specific sequencing data show that this new mutation occurs in the allele that harbors original activation mutation of KIT.

31 keywords...

hide…